Tango Therapeutics, Inc. $TNGX Shares Bought by Profund Advisors LLC

Profund Advisors LLC raised its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 167.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,759 shares of the company’s stock after buying an additional 52,471 shares during the quarter. Profund Advisors LLC owned about 0.06% of Tango Therapeutics worth $742,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd lifted its position in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares during the last quarter. Legal & General Group Plc lifted its position in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after buying an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Tango Therapeutics in the fourth quarter valued at about $40,000. Finally, Tower Research Capital LLC TRC lifted its position in Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after buying an additional 2,907 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on TNGX. Canaccord Genuity Group initiated coverage on shares of Tango Therapeutics in a research report on Thursday, April 2nd. They issued a “buy” rating and a $30.00 target price on the stock. Guggenheim increased their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Mizuho increased their price target on shares of Tango Therapeutics from $20.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Leerink Partners increased their price target on shares of Tango Therapeutics from $28.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Piper Sandler cut shares of Tango Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $16.00 to $24.00 in a research report on Thursday, May 14th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $32.27.

Insiders Place Their Bets

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $21.23, for a total value of $573,210.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at $2,457,223.89. This trade represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 179,056 shares of company stock valued at $3,346,181 over the last 90 days. 6.50% of the stock is owned by company insiders.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $20.24 on Friday. The stock has a market capitalization of $2.93 billion, a PE ratio of -24.39 and a beta of 1.22. Tango Therapeutics, Inc. has a 1 year low of $1.79 and a 1 year high of $28.41. The company’s 50-day simple moving average is $21.98 and its 200-day simple moving average is $14.69.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. On average, sell-side analysts predict that Tango Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.